Final Guidance From FDA Recommends Study Approach For Glycemic Control Devices
Executive Summary
The document explains how the US agency wants researchers to conduct early-stage studies of the devices, which attempt to control blood sugar through bariatric, neurostimulation, and other treatments.
You may also be interested in...
New Draft Guidance From US FDA Discusses Trials For Novel Diabetes Treatments
The document discusses feasibility studies on devices that use therapies like neurostimulation or changes to the small intestine to better control blood glucose levels in people with type 2 diabetes.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.